Literature DB >> 25475463

Risk stratification and clinical pathways to optimize length of stay after transcatheter aortic valve replacement.

Sandra B Lauck1, David A Wood2, Leslie Achtem3, Jennifer Baumbusch4, Robert H Boone2, Anson Cheung2, Danny Dvir3, Dion Stub3, John S Tan3, Jian Ye2, John G Webb2.   

Abstract

BACKGROUND: Transcatheter aortic valve replacement (TAVR) program experience and advances present opportunities to introduce minimalist clinical pathways. The purpose of this study was to determine the safety and feasibility of preprocedural individualized risk stratification for general anaesthesia and transesophageal echocardiography (GA/TEE) or awake TAVR and the postprocedural standard or rapid discharge TAVR clinical pathways.
METHODS: Standardized screening and multidisciplinary heart team consensus was used to evaluate individual periprocedural risk and requirements. Postprocedural clinical status and criteria guided the timing of discharge. We evaluated standardized TAVR outcomes and length of stay according to periprocedural practice and postprocedural trajectory.
RESULTS: In 144 consecutive patients who underwent TAVR in 2013 (mean age, 82.0 ± 7.1 years; 38.2% women; mean Society of Thoracic Surgeons score, 6.5% ± 4.1%), 101 (69.1%) were assigned to the GA/TEE protocol, whereas 43 (29.9%) were assigned to the minimalist awake TAVR protocol. Irrespective of mode of anaesthesia, 94 (65.3%) patients were discharged within the standard time, whereas 50 (34.7%) patients were suitable for rapid discharge. Overall outcomes at 30 days were 2.1% mortality, 1.4% stroke, and 2.1% life-threatening bleeding. Median length of stay was shortest in the awake TAVR group (2 days; interquartile range [IQR], 1-3 days) and rapid discharge group (2 days; IQR, 1-2 days) and longer in the GA/TEE and standard discharge (3 days, IQR, 3-4 days) groups.
CONCLUSIONS: Excellent outcomes and decreased length of stay can be achieved with individualized risk stratification to select the optimal periprocedural practice and determine the timing of discharge. These findings should be further evaluated in a large long-term clinical study.
Copyright © 2014 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25475463     DOI: 10.1016/j.cjca.2014.07.012

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  6 in total

1.  Safe implementation of enhanced recovery after surgery protocol in transfemoral transcatheter aortic valve replacement.

Authors:  Molly Szerlip; Deborah Tabachnick; Mohanad Hamandi; LuAnn Caras; Allison T Lanfear; John J Squiers; Katherine Harrington; Srinivasa P Potluri; J Michael DiMaio; Jordan Wooley; Benjamin Pollock; Justin M Schaffer; William T Brinkman; David L Brown; Michael J Mack
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-09-23

Review 2.  The transition from transesophageal to transthoracic echocardiography during transcatheter aortic valve replacement: an evolving field.

Authors:  Menhel Kinno; Eric P Cantey; Vera H Rigolin
Journal:  J Echocardiogr       Date:  2018-11-21

3.  Risk Assessment of Patients Undergoing Transfemoral Aortic Valve Implantation upon Admission for Post-Interventional Intensive Care and Surveillance: Implications on Short- and Midterm Outcomes.

Authors:  Fadi Al-Rashid; Philipp Kahlert; Friederike Selge; Heike Hildebrandt; Polycarpos-Christos Patsalis; Matthias Totzeck; Petra Mummel; Tienush Rassaf; Rolf Alexander Jánosi
Journal:  PLoS One       Date:  2016-11-23       Impact factor: 3.240

4.  Factors associated with length of stay following trans-catheter aortic valve replacement - a multicenter study.

Authors:  Yaron Arbel; Nevena Zivkovic; Dhruven Mehta; Sam Radhakrishnan; Stephen E Fremes; Effat Rezaei; Asim N Cheema; Sami Al-Nasser; Ariel Finkelstein; Harindra C Wijeysundera
Journal:  BMC Cardiovasc Disord       Date:  2017-05-26       Impact factor: 2.298

5.  Sleep in octogenarians during the postoperative phase after transcatheter or surgical aortic valve replacement.

Authors:  Hege Andersen Amofah; Anders Broström; Bengt Fridlund; Bjørn Bjorvatn; Rune Haaverstad; Karl Ove Hufthammer; Karel Kj Kuiper; Anette Hylen Ranhoff; Tone M Norekvål
Journal:  Eur J Cardiovasc Nurs       Date:  2015-12-03       Impact factor: 3.908

6.  Drivers of healthcare costs associated with the episode of care for surgical aortic valve replacement versus transcatheter aortic valve implantation.

Authors:  Harindra C Wijeysundera; Lindsay Li; Vevien Braga; Nandhaa Pazhaniappan; Anar M Pardhan; Dana Lian; Aric Leeksma; Ben Peterson; Eric A Cohen; Anne Forsey; Kori J Kingsbury
Journal:  Open Heart       Date:  2016-08-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.